Florfenicol

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Animals1

Outcomes

AMPK signalling

upin mice1

1 study

Florfenicol activates AMPK signalling in mice.
“FLO effectively inhibits colon senescence and treats DSS-induced colitis by activating the AMPK signaling pathway.”
Animalsin DSS-induced colitis
Protective effect of Florfenicol against DSS-induced ulcerative colitis by inhibiting cellular senescence and reducing inflammation via the AMPK signaling pathway
Toxicology and applied pharmacology8 Feb 2026

Latest

1 in 12 months

Toxicology and Applied Pharmacology11 Feb

Protective effect of Florfenicol against DSS-induced ulcerative colitis by inhibiting cellular senescence and reducing inflammation via the AMPK signaling pathway

Experiments in miceInterventions

Paper

Florfenicol

Outcomes

Latest

Protective effect of Florfenicol against DSS-induced ulcerative colitis by inhibiting cellular senescence and reducing inflammation via the AMPK signaling pathway

Related